501 related articles for article (PubMed ID: 16698355)
1. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
[TBL] [Abstract][Full Text] [Related]
2. The value of the ImmunoCyt/uCyt+ test in the detection and follow-up of carcinoma in situ of the urinary bladder.
Mian C; Lodde M; Comploj E; Palermo S; Mian M; Maier K; Pycha A
Anticancer Res; 2005; 25(5):3641-4. PubMed ID: 16101194
[TBL] [Abstract][Full Text] [Related]
3. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses.
Mian C; Maier K; Comploj E; Lodde M; Berner L; Lusuardi L; Palermo S; Vittadello F; Pycha A
Cancer; 2006 Feb; 108(1):60-5. PubMed ID: 16411183
[TBL] [Abstract][Full Text] [Related]
4. uCyt+/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.
Comploj E; Mian C; Ambrosini-Spaltro A; Dechet C; Palermo S; Trenti E; Lodde M; Horninger W; Pycha A
Cancer Cytopathol; 2013 Jul; 121(7):392-7. PubMed ID: 23495066
[TBL] [Abstract][Full Text] [Related]
5. [Contribution of fluorescence immunocytochemistry (uCyt+TM) in the postoperative surveillance of bladder cancer].
Piaton E; Ruffion A; Collet F; Lopez JG; Champetier D; Hoch M; Perrin P; Devonec M
Prog Urol; 2004 Jun; 14(3):315-9; discussion 319. PubMed ID: 15373172
[TBL] [Abstract][Full Text] [Related]
6. [ImmunoCyt--a new urine test in diagnosis of bladder cancer].
Feil G; Bichler KH; Päulgen-Nelde HJ; Hennenlotter J; Zumbrägel A; Stenzl A
Urologe A; 2003 Apr; 42(4):531-7. PubMed ID: 12715125
[TBL] [Abstract][Full Text] [Related]
7. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
8. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravesical instillation on performance of uCYT+ test.
Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A
Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970
[TBL] [Abstract][Full Text] [Related]
10. Intermediate-risk urothelial carcinoma: an unresolved problem?
Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
[TBL] [Abstract][Full Text] [Related]
11. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
12. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
13. [Value of the uCyt+ test for the detection and followup of bladder tumors].
Drapier E; Renaudin K; Maillet F; Braud G; Laboisse C; Bouchot O
Prog Urol; 2003 Apr; 13(2):222-6. PubMed ID: 12765055
[TBL] [Abstract][Full Text] [Related]
14. [The BTA stat test in the follow-up for bladder cancer].
Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
[TBL] [Abstract][Full Text] [Related]
15. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J
Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400
[TBL] [Abstract][Full Text] [Related]
16. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
18. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology.
Daniely M; Rona R; Kaplan T; Olsfanger S; Elboim L; Freiberger A; Lew S; Leibovitch I
Cancer; 2007 Dec; 111(6):517-24. PubMed ID: 17963263
[TBL] [Abstract][Full Text] [Related]
19. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
20. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison.
Hautmann S; Toma M; Lorenzo Gomez MF; Friedrich MG; Jaekel T; Michl U; Schroeder GL; Huland H; Juenemann KP; Lokeshwar VB
Eur Urol; 2004 Oct; 46(4):466-71. PubMed ID: 15363562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
